Telix Pharmaceuticals Ltd

TLX Details
 
Recently Listed on ASX: Telix Pharmaceuticals Ltd (ASX: TLX), emerging as a leading player in the molecular targeted radiation (MTR) market, has appointed Dr. Bernard Lambert as President and Chief Operating Officer (COO) of TLX US subsidiary. He will manage the growing US manufacturing infrastructure, providing operational support for US-based clinical trials and establish the team to support TLX near-term commercialization objectives in renal and prostate cancer imaging. On the other hand, TLX in the first half has posted the loss from continuing operations of $24,360. TLX had raised $8.5 million in advance of an initial public offering (IPO) to start its research and development programs, that include TLX-101 (a product candidate to treat Glioblastoma).
 

1H 17 Financial Performance (Source: Company Reports)
 
The group’s programs on TLX-250 relating to Renal cancer imaging is progressing well with high chance of approval being sought. Moreover, the company had raised $50.05 million by the offer of 77,000,000 ordinary shares at $0.65 per share through the IPO.  Meanwhile, TLX stock has fallen 22.08% since trading from mid of November 2017, and does not have any detailed history. While the group is currently pre-revenue, the advanced stage of TLX-250 and progress on other programs are anticipated to help Telix start revenue generation within 2 years. Based on the foregoing, we give a “Speculative Buy” recommendation on the stock at the current price of $0.585


TLX Daily Chart (Source: Thomson Reuters)
 

eServGlobal Ltd

ESV Details
 
Raising Fund: eServGlobal Ltd (ASX: ESV) is raising approximately £24.0 million through an Entitlement offer. The company has completed the “Retail Offer”, and had raised approximately £15.8 million through the “Institutional Offer”. Moreover, ESV’s core business will be realising M&A value in 2018, in which a right-sized operational EBITDA breakeven point is of €12m.
 

Use of proceeds (Source: Company Reports)
 
The company expects operational EBITDA to breakeven in quarter to December 2017. However, the company will not be able to post enough revenue to recover from the disappointing first half of the year. As a result, ESV expects a lower revenue range for the 14-month period than previously expected, in the range of €9.7 to €11.0m; while positive momentum is expected from improved orders. Additionally, for the significant sales expansion of HomeSend, the agreements are signed with banks, including contracts with Standard Chartered, KEB Hana Bank and Atlas Mara. The annual volumes from signed opportunities are expected to be US$3bn-$5bn in the medium term. In addition, ESV expects to strengthen its balance sheet by reducing Lombard Odier debt. The company intends to maintain HomeSend stake at 35% with flexibility for future investment. Furthermore, after the completion of cost reduction plans, the core business is expected to be self-sustaining next year on a stand-alone basis. Meanwhile, ESV stock has risen 74.41% in three months as on December 11, 2017 and was up over 5% on December 12, 2017. However, based on the foregoing, we give a “Speculative Buy” recommendation on the stock at the current price of $0.195


ESV Daily Chart (Source: Thomson Reuters)
 

Dotz Nano Ltd

DTZ Details
 
Raised funds for commercialisation activities: Dotz Nano Ltd (ASX: DTZ) has recently completed its capital raising, and in accordance with the terms of a placement, has issued 18,333,333 shares (under tranche 1) at an issue price of $0.18 per share. DTZ has raised AUD$3.8 million by the placement of shares, which will be utilised as working capital for commercialisation activities. Moreover, DTZ is in advanced negotiations with a major Chinese optoelectronics manufacturer, for a significant and potentially controlling investment into the company’s subsidiaries for utilisation of its GQD (graphene quantum dots) technology. The negotiations are incomplete and confidential and therefore any information whether on any agreement being reached, or that any investment or transaction will eventuate, have not been revealed at this stage. Further, DTZ is in advanced negotiations with a major Australian automotive solvent manufacturer and a major USA automotive solvent manufacturer for implementation of GQDs as an anti-counterfeiting mechanism. Additionally, DTZ has signed a Joint Collaboration Agreement with UltraCharge Ltd for its use of GQDs in their anode technology for Lithium ion batteries. After the successful completion of the pilot program, UltraCharge will place an initial order of a minimum US$150,000 worth of GQDs for use in LIB anodes. The initial order is subject to UltraCharge receiving purchase orders of at least $1 million dollars for their GQD enriched anodes. Furthermore, DTZ has received its first major order of GQDs of AU$135,000. The order was facilitated through DTZ’s Japanese distributor for supply to Japanese and Pan-Asian companies in the anti-counterfeiting market and optical brightener for polymers. On the other hand, DTZ stock has risen 33.33% in three months as on December 11, 2017. We give a “Speculative Buy” recommendation on the stock at the current price of $0.18


DTZ Daily Chart (Source: Thomson Reuters)

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.